Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EBITDA: 2015-2025

Historic EBITDA for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to -$22.5 million.

  • Seres Therapeutics' EBITDA fell 125.32% to -$22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.2 million, marking a year-over-year decrease of 254.19%. This contributed to the annual value of $136,000 for FY2024, which is 100.12% up from last year.
  • Per Seres Therapeutics' latest filing, its EBITDA stood at -$22.5 million for Q3 2025, which was up 9.66% from -$24.9 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' EBITDA ranged from a high of $88.8 million in Q3 2024 and a low of -$71.2 million during Q1 2023.
  • In the last 3 years, Seres Therapeutics' EBITDA had a median value of -$27.2 million in 2025 and averaged -$17.1 million.
  • As far as peak fluctuations go, Seres Therapeutics' EBITDA spiked by 325.29% in 2021, and later plummeted by 187.76% in 2022.
  • Quarterly analysis of 5 years shows Seres Therapeutics' EBITDA stood at -$50.1 million in 2021, then plummeted by 37.18% to -$68.7 million in 2022, then spiked by 39.95% to -$41.2 million in 2023, then surged by 62.09% to -$15.6 million in 2024, then tumbled by 125.32% to -$22.5 million in 2025.
  • Its last three reported values are -$22.5 million in Q3 2025, -$24.9 million for Q2 2025, and -$27.2 million during Q1 2025.